Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab versus cyclophosphamide in severe mucous membrane pemphigoid
2016-004666-26Phase 3Active
- Sponsor
- Rouen University Hospital
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cicatricial pemphigoid (CP) and ocular cicatricial pemphigoid (OCP) comparing Rituximab + dapsone with Cyclophosphamide + dapsone (2 arms). Started Jul 2024; status: active.
02
Drugs
rituximabcyclophosphamidedapsone
03
Conditions
cicatricial pemphigoid (CP)ocular cicatricial pemphigoid (OCP)
Beyond the preview
Go deeper on 2016-004666-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004666-26.